A dendritic cell vaccine personalized for each individual based on the patient’s own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA’s Jonsson Comprehensive Cancer Center has found. The results are published this week in the peer-reviewed journal Clinical Cancer Research.
CSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age. The team found that extremely low doses of the drug lenalidomide can stimulate the body’s immune-cell protein factories, which decrease production during aging, […]
Clinical trials using patients’ own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver […]
Recent Comments